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Applying evidence-based symptomatic treatments from other clinical disciplines to 
palliative care 
 
The evidence base for palliative care has seen a steady increase in the number of high-quality 
randomised controlled studies that have significantly contributed to improving patients’ and 
caregivers’ care in this setting. Adequately powered phase III studies are the gold standard in 
establishing a causal link between the intervention and the outcome. Ideally, studies 
conducted in other clinical disciplines (with comparable populations) would be repeated in 
palliative care populations to confirm the benefits and harms of any proposed non-
pharmacological or pharmacological intervention but this is costly, time-consuming, resource 
intensive and may be difficult to justify ethically if the results from another clinical discipline 
can reasonably be applied to palliative care patients. 
 
Many therapies for symptoms need an evidence base for safe and effective management. The 
evidence generated from studies conducted in palliative care populations is a fraction of 
potentially applicable knowledge currently available that has direct relevance to palliative 
care. There is already a large evidence base for symptom control developed in patient 
populations that may be analogous to those in palliative care. One way to complement the 
available evidence generated by palliative care studies to further improve clinical practice is 
to apply findings from symptom control studies conducted in other clinical disciplines. The 
careful extrapolation of findings from other clinical disciplines into palliative care can help 
advance the evidence base for improved palliative care clinical practice by addressing some 
current gaps in knowledge on symptomatic treatments. 
 
In evidence-based practice, application of knowledge to clinical decisions relies on the 
researchers’ ability to target a defined and reproducible population representative of broader 
populations or clinical care settings to optimise generalisability, and the clinicians’ ability to 
determine sufficient similarities between the population studied and the individual patient to 
optimise applicability. Formal frameworks have been proposed to maximise the researchers’ 
ability to describe the palliative care populations in their studies so clinicians can make more 
informed decisions when applying the findings to their practice.1 There is a need for similar 
formal methods to maximise the clinicians’ ability to make informed decisions about the 
applicability of interventions where the evidence has been developed in disciplines other than 
palliative care. 
 
Applicability is applying research findings to a patient,2 ultimately asking ‘will this person 
react in a similar way to the intervention for a similar net clinical effect (benefits and 
harms)?’1 Applicability of findings across disciplines (or “clinical transferability”3) relies on 
evaluating the therapeutic intervention in the context of the population and setting in which 
the intervention was studied.1,3 Assessing applicability requires clinicians to have critical 
appraisals skills to interpret the relevance of each study’s findings for the patients they serve, 
and incorporate relevant findings into their own practice.1 
 
Applicability facilitates effective translation of relevant research into clinical practice. In 
palliative care, translating evidence into practice is challenging due to differences in patient 
characteristics (where lack of agreed referral criteria creates a heterogeneous case-mix in a 
specialty that relies on referral from a wide range of other clinicians); differences in the 
service profile (where time from referral to death can differ greatly4); or interventions that 
may have different effects late in life. Funding imposes further potential constraints5 as do 
differing measures used to assess clinical outcomes.6 Additionally, data in other disciplines 
may be collected using disease-specific instruments with which palliative care clinicians may 
not be familiar. All of this means clinicians will need to “equate” the study results to their 
actual practice before they can apply the proposed treatments in the knowledge that such 
therapies are appropriate for their patients. 
 
A way forward 
 
Despite these challenges, applying evidence from other clinical disciplines into palliative care 
offers exciting opportunities to accelerate the evidence base for symptom control. If applying 
knowledge from other disciplines is desirable, what factors should guide this process and help 
clinicians to undertake this evaluation for their population with confidence? Furthermore, if 
knowledge has been applied from another discipline, how do we evaluate the subsequent net 
effect in palliative care without repeating the original studies? 
 
Applying evidence from other clinical disciplines into palliative care requires a rigorous and 
transparent process to balance potential benefits and harms of the research findings when 
applied to palliative care patients. Several key factors should guide palliative care clinicians’ 
evaluation of research findings from other clinical disciplines to help optimise the use of  
beneficial interventions and limit inappropriate interventions,7 for individual patients and 
populations. First, the study population: this would include identifying the demographic and 
clinical profile of patients (or caregivers) in both the original study and those to whom it may 
apply in palliative care. General population descriptors can help determine similarities and 
differences between study and patient populations, and caregiver factors are important if the 
intervention requires supervision or caregivers to administer it. Second, the symptom: this 
would include identifying any similarities in the underlying pathophysiology between 
patients in the original study and those seen in palliative care, the clinical presentation of the 
symptom when compared to palliative care patients and the way symptoms are assessed in 
the disciplines under consideration. Third, the intervention evaluated: this should include 
details such as the time to onset of benefit and duration of benefit when evaluating its 
applicability in patients with limited prognosis and reduced physical reserve, the effect size 
seen with the proposed therapy and whether that would be acceptable for palliative care 
populations, any contraindications for the new target population, and risks of drug/drug or 
drug/host interactions in the palliative care population, given the patterns of prescribing for 
co-morbid diseases and for symptom control.8 Fourth, the quality and strength of the 
evidence: this should include identifying confirmatory studies with the same direction and 
magnitude of net effects for the proposed intervention, or potentially contradictory studies for 
the same indication. Fifth, the setting of care: this should include identifying issues around 
safety monitoring and patient compliance and how similar those are between the original 
study and those seen in palliative care, or whether the trial setting can be replicated in routine 
palliative care, and findings applied across clinical settings (e.g. specialist vs primary care, 
inpatient vs community). Sixth, the availability of the intervention: this would include issues 
around cost and accessibility of the proposed intervention in palliative care. In addition to this 
assessment, quality measures of the originating study would have to be considered to assess 
risk of bias when exploring the study’s internal validity. 
 
A formal framework with this kind of clinical focus, similar to those guiding generalisability 
of clinical research,1 would introduce a degree of rigour in navigating the effective translation 
of findings across disciplines in palliative care, potentially further improving patients’ and 
caregivers’ outcomes. Ideally, this would also be complemented with guidelines at the 
service, funding and policy levels that would support a collaborative clinical research model 
for advancing the science and practice of palliative care. 
 
Implications for clinical research and practice 
 
Using existing evidence from other clinical disciplines to inform palliative care practice can 
be scientifically sound and cost-effective. Having made the decision to apply knowledge 
from another discipline, post-marketing frameworks can be used to monitor the direction and 
magnitude of net effects in palliative care patients. Post-marketing surveillance (phase IV) 
studies can be the first critical step in evaluating the net effect of findings applied from other 
disciplines into palliative care by monitoring real-world outcomes,7 including drug 
interactions9 and toxicities.10 Using a rigorous methodology,11 such studies can add to 
knowledge from the original phase III study when applied in the palliative care setting. 
 
Patients and families deserve the best possible care when faced with a life-limiting illness and 
rapidly changing life circumstances. Irrespective of the delivery setting and models of care, 
palliative care clinicians should be able to quickly and confidently work with the available 
evidence to provide much needed symptom relief and support to their patients and caregivers. 
With many symptomatic treatments still in development and awaiting validation in palliative 
care populations, applying relevant findings from other clinical discipline systematically can 
facilitate more effective translation of research findings into clinical practice and help 
accelerate building the evidence base by bringing high quality symptom control studies in 
comparable populations into palliative care. Post-marketing studies also have an important 
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